使用小分子托波特干化物向STAT5,可以抑制急性髓性白血病的进展
Jiahui Li1, Bin Tang2, Ying Miao3
1Fengxian Hospital Affiliated to Anhui University of Science and Technology, Shanghai 201499, P.R. China.
Oncology reports
|October 13, 2023
概括
研究人员将托波特干化物确定为一种针对STAT5的新型小分子抑制剂,为急性髓性白血病 (AML) 和其他血液恶性瘤提供了有前途的新疗法.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 急性髓性白血病 (AML) 是一种流行成人白血病,复发率高,通常与FLT3-ITD突变有关.
- 由FLT3-ITD驱动的STAT5激活与AML的发病有关,并与预后不佳和药物耐药性有关.
- 准STAT5为AML治疗提供了重要的临床机会.
研究的目的:
- 确定和描述一种针对STAT5的小分子抑制剂,用于AML治疗.
- 评估针对AML细胞系和临床前模型的鉴定抑制剂的疗效.
主要方法:
- 为STAT5.5开发和实施高通量光极化 (FP) 选系统.
- 对化合物库进行选,以识别STAT5抑制剂.
- 分子对接,细胞热转移试验 (CETSA) 和细胞试验以验证抑制剂活性.
- 对AML细胞系,包括FLT3-ITD+细胞的抗增殖作用的评估.
主要成果:
- 托波特坎化通过FP查被确定为一种强大的STAT5抑制剂.
- 分子对接和CETSA证实了托波特坎化与STAT5.5的结合.
- 该化合物在纳米分子度下有效抑制STAT5二分化,酸化和基因转录.
- 托波特干化物显著抑制了人类AML细胞系的增殖,包括FLT3-ITD+AML细胞.
- 观察到临床前体内抗瘤活性.
结论:
- 托波特坎化是一种新的,有效的小分子抑制剂STAT5.
- 这种化合物通过直接向STAT5.5来治疗AML和其他血液恶性瘤显著有前途.
- 直接抑制STAT5代表了AML的可行的治疗策略,特别是在FLT3-ITD突变病例中.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Tumor Immunotherapy
539
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
539
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K


